HOME >> BIOLOGY >> NEWS
Tramiprosate (Alzhemed) preclinical results published in Neurobiology of Aging

on and the trial is scheduled to be completed by January 2007. All patients who complete the North American Phase III clinical trial will be offered the opportunity to receive tramiprosate (Alzhemed) in an open-label extension study.

Neurochem is also actively advancing an 18-month Phase III clinical trial for tramiprosate (Alzhemed) in Europe, which was initiated in September 2005. The ongoing European Phase III clinical trial, an international, multi-center, randomized, double-blind, placebo-controlled and parallel-designed study, is progressing on schedule and will investigate the safety, efficacy and disease-modifying potential of tramiprosate (Alzhemed). Some 930 mild-to-moderate AD patients are expected to take part and enrollment is expected to be completed in the fall of 2006.

About Alzheimer's disease
Alzheimer's disease (AD) is a progressive form of dementia associated with specific brain pathologies. It impairs a person's cognitive and motor functions, their activities of daily living, alters the behaviour and gradually destroys the brain.

AD is the most common cause of dementia in our aging population. Almost 5 million individuals in the United States alone currently suffer from the condition. The U.S. Alzheimer's Association estimates that by 2025, over 22 million people worldwide will be afflicted.

According to a report commissioned by the U.S. Alzheimer's Association, AD costs American businesses approximately US$61 billion a year. That price tag includes US$24.6 billion for direct health care of Alzheimer's patients and US$36.5 billion to cover costs related to caregivers of AD patients, including lost productivity, absenteeism and worker replacement.


'"/>

Contact: Lise Hébert, PhD
lhebert@neurochem.com
450-680-4570
Neurochem, Inc.
30-May-2006


Page: 1 2 3

Related biology news :

1. Serica scientists win AOSSM Award for ACL (knee) tissue regeneration in preclinical study
2. Promising preclinical results with live attenuated H5N1 vaccines
3. Fatty spheres loaded with siRNA shrink ovarian cancer tumors in preclinical trial
4. Cytori demonstrates adipose stem cells improve cardiac function in preclinical heart attack model
5. Cooperative science program yields results
6. Delayed treatment of childhood-onset bipolar disorder results in negative outcome in adults
7. Smelling for first time results from knowing abnormalities in congenital loss of smell
8. BDSI announces positive phase III clinical trial results
9. Scientists meet to review Envisat results after 5 years of operations
10. Environment and exercise may affect research results, UA study shows
11. Preliminary results of largest scan of autism DNA information

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/1/2016)... , June 1, 2016 Favorable ... Election Administration and Criminal Identification to Boost Global Biometrics ... recently released TechSci Research report, " Global Biometrics Market ... Competition Forecast and Opportunities, 2011 - 2021", the global ... by 2021, on account of growing security concerns across ...
(Date:5/9/2016)... , UAE, May 9, 2016 ... when it comes to expanding freedom for high net ... Even in today,s globally connected world, there is ... conferencing system could ever duplicate sealing your deal with ... obtaining second passports by taking advantage of citizenship via ...
(Date:4/26/2016)... April 27, 2016 Research ... Multi-modal Biometrics Market 2016-2020"  report to their offering.  ... The analysts forecast the global multimodal ... 15.49% during the period 2016-2020.  Multimodal ... sectors such as the healthcare, BFSI, transportation, automotive, ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... ... 2016 , ... In a new case report published today in STEM CELLS ... developed lymphedema after being treated for breast cancer benefitted from an injection of stem ... with this debilitating, frequent side effect of cancer treatment. , Lymphedema refers ...
(Date:6/23/2016)... Calif. , June 23, 2016  Blueprint Bio, ... biological discoveries to the medical community, has closed its ... Matthew Nunez . "We have received ... with the capital we need to meet our current ... essentially provide us the runway to complete validation on ...
(Date:6/23/2016)... -- On Wednesday, June 22, 2016, the NASDAQ ... Dow Jones Industrial Average edged 0.27% lower to finish at ... Stock-Callers.com has initiated coverage on the following equities: Infinity Pharmaceuticals ... NKTR ), Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ ... Learn more about these stocks by accessing their free trade ...
(Date:6/23/2016)... ... June 23, 2016 , ... Regulatory Compliance ... consulting, provides a free webinar on Performing Quality Investigations: Getting to ... 12pm CT at no charge. , Incomplete investigations are still a major concern ...
Breaking Biology Technology:
Cached News: